Pharming launches Joenja in Japan for APDS patients
Pharming (NASDAQ:PHAR) announced the commercial launch of Joenja (leniolisib) in Japan for patients aged 4 years and older with activated PI3K delta syndrome (APDS), following its inclusion on Japan’s National Health Insurance drug price list.











